Generic Crexont Availability
Last updated on Apr 10, 2025.
Crexont is a brand name of carbidopa/levodopa, approved by the FDA in the following formulation(s):
CREXONT (carbidopa; levodopa - capsule, extended release;oral)
-
Manufacturer: IMPAX
Approval date: August 7, 2024
Strength(s): 35MG;140MG [RLD], 52.5MG;210MG [RLD], 70MG;280MG [RLD], 87.5MG;350MG [RLD]
Is there a generic version of Crexont available?
No. There is currently no therapeutically equivalent version of Crexont available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Crexont. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
Patent 10,098,845
Issued: October 16, 2018
Inventor(s): Hsu Ann & Dong Liang C. & Ding Amy & Gupta Suneel
Assignee(s): IMPAX LABORATORIES, LLCThe invention provides a controlled release oral solid formulation comprising (a) a controlled release component comprising core comprising levodopa and/or an ester of levodopa or salts thereof, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric coated polymer; and (b) a decarboxylase inhibitor component.
Patent expiration dates:
- October 7, 2034✓✓
- October 7, 2034
-
Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
Patent 10,292,935
Issued: May 21, 2019
Inventor(s): Hsu Ann & Dong Liang C. & Ding Amy & Gupta Suneel
Assignee(s): Impax Laboratories, Inc.The invention provides a controlled release oral solid formulation comprising (a) a controlled release component comprising core comprising levodopa and/or an ester of levodopa or salts thereof, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric coated polymer; and (b) a decarboxylase inhibitor component.
Patent expiration dates:
- October 7, 2034✓✓
- October 7, 2034
-
Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
Patent 10,688,058
Issued: June 23, 2020
Inventor(s): Hsu Ann & Dong Liang & Ding Amy & Gupta Suneel
Assignee(s): Impax Laboratories, LLCThe invention provides a controlled release oral solid formulation comprising (a) a controlled release component comprising core comprising levodopa and/or an ester of levodopa or salts thereof, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric coated polymer; and (b) a decarboxylase inhibitor component.
Patent expiration dates:
- October 7, 2034✓✓
- October 7, 2034
-
Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
Patent 10,973,769
Issued: April 13, 2021
Inventor(s): Hsu; Ann et al.
Assignee(s): Impax Laboratories, LLC (Bridgewater, NJ)The invention provides a controlled release oral solid formulation comprising (a) a controlled release component comprising core comprising levodopa and/or an ester of levodopa or salts thereof, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric coated polymer; and a method of using the controlled release oral solid formulation to treat Parkinson's disease or primary parkinsonism.
Patent expiration dates:
- October 7, 2034✓✓
- October 7, 2034
-
Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
Patent 10,987,313
Issued: April 27, 2021
Inventor(s): Hsu; Ann et al.
Assignee(s): Impax Laboratories, LLC (Bridgewater, NJ)The invention provides a controlled release oral solid formulation comprising (a) a controlled release component comprising core comprising levodopa and/or an ester of levodopa or salts thereof, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric coated polymer; and (b) a decarboxylase inhibitor component.
Patent expiration dates:
- October 7, 2034✓✓
- October 7, 2034
-
Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
Patent 11,357,733
Issued: June 14, 2022
Inventor(s): Hsu Ann & Dong Liang & Ding Amy & Gupta Suneel
Assignee(s): Impax Laboratories, LLCThe invention provides a controlled release oral solid formulation comprising (a) a controlled release component comprising core comprising levodopa and/or an ester of levodopa or salts thereof, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric coated polymer; and (b) a decarboxylase inhibitor component.
Patent expiration dates:
- October 7, 2034✓
- October 7, 2034
-
Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
Patent 11,622,941
Issued: April 11, 2023
Inventor(s): Hsu; Ann et al.
Assignee(s): Impax Laboratories, LLC (Bridgewater, NJ)The invention provides an oral solid formulation comprising (a) a controlled release component comprising a core comprising levodopa, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric polymer; and (b) an immediate release component comprising carbidopa and levodopa.
Patent expiration dates:
- October 7, 2034✓
- October 7, 2034
-
Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
Patent 11,666,538
Issued: June 6, 2023
Inventor(s): Hsu; Ann et al.
Assignee(s): Impax Laboratories, LLC (Bridgewater, NJ)The invention provides an oral solid formulation comprising (a) a controlled release component comprising a core comprising levodopa, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric polymer; and (b) an immediate release component comprising carbidopa and levodopa.
Patent expiration dates:
- October 7, 2034✓✓
- October 7, 2034
-
Levodopa dosing regimen
Patent 11,986,449
Issued: May 21, 2024
Inventor(s): D'Souza; Richard et al.
Assignee(s): Amneal Pharmaceuticals LLC (Bridgewater, NJ)The invention provides oral dosing regimens of controlled release levodopa compositions for use in treating patients with Parkinson's disease, primary parkinsonism/idiopathic parkinsonism, post-encephalitic parkinsonism, parkinsonism that may follow carbon monoxide intoxication, or parkinsonism that may follow manganese intoxication.
Patent expiration dates:
- December 21, 2041✓
- December 21, 2041
-
Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
Patent 12,064,521
Issued: August 20, 2024
Inventor(s): Hsu; Ann et al.
Assignee(s): Impax Laboratories, LLC (Bridgewater, NJ)The invention provides an oral solid formulation comprising (a) a controlled release component comprising a core comprising levodopa, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric polymer; and (b) an immediate release component comprising levodopa.
Patent expiration dates:
- October 7, 2034✓
- October 7, 2034
-
Levodopa dosing regimen
Patent 12,109,185
Issued: October 8, 2024
Inventor(s): D'Souza; Richard et al.
Assignee(s): Amneal Pharmaceuticals, LLC (Bridgewater, NJ)The invention provides oral dosing regimens of controlled release levodopa compositions for use in treating patients with Parkinson's disease, primary parkinsonism/idiopathic parkinsonism, post-encephalitic parkinsonism, parkinsonism that may follow carbon monoxide intoxication, or parkinsonism that may follow manganese intoxication and the dosing regimens provide an improvement of a patient's total post-dose “On” time or “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.
Patent expiration dates:
- December 21, 2041✓
- December 21, 2041✓
- December 21, 2041✓
- December 21, 2041✓
- December 21, 2041
-
Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof
Patent 12,128,141
Issued: October 29, 2024
Inventor(s): Hsu; Ann et al.
Assignee(s): Impax Laboratories, LLC (Bridgewater, NJ)The invention provides an oral solid formulation comprising (a) a controlled release component comprising a core comprising levodopa, wherein the core is coated with a muco-adhesive coating and the muco-adhesive coating is externally coated with an enteric coating; and (b) an immediate release component comprising levodopa. The invention further provides a method for making and using the oral solid formulation.
Patent expiration dates:
- October 7, 2034✓✓
- October 7, 2034
-
Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
Patent 12,178,918
Issued: December 31, 2024
Inventor(s): Hsu; Ann et al.
Assignee(s): Impax Laboratories, LLC (Bridgewater, NJ)The invention provides an oral solid formulation comprising (a) a controlled release component comprising a core comprising levodopa, wherein the core is coated with a muco-adhesive coating and the muco-adhesive coating is externally coated with an enteric coating; and (b) an immediate release component comprising levodopa. The invention further provides a method for making and using the oral solid formulation.
Patent expiration dates:
- October 7, 2034✓
- October 7, 2034
-
Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof
Patent 12,178,919
Issued: December 31, 2024
Inventor(s): Hsu; Ann et al.
Assignee(s): Impax Laboratories, LLC (Bridgewater, NJ)The invention provides an oral solid formulation comprising (a) a controlled release component comprising a core comprising levodopa, wherein the core is coated with a muco-adhesive coating and the muco-adhesive coating is externally coated with an enteric coating; and (b) an immediate release component comprising levodopa. The invention further provides a method for making and using the oral solid formulation.
Patent expiration dates:
- October 7, 2034✓✓
- October 7, 2034
-
Levodopa dosing regimen
Patent 12,194,150
Issued: January 14, 2025
Inventor(s): D'Souza; Richard et al.
Assignee(s): Amneal Pharmaceuticals LLC (Bridgewater, NJ)The invention provides oral dosing regimens of controlled release levodopa compositions for use in treating patients with Parkinson's disease.
Patent expiration dates:
- December 21, 2041✓
- December 21, 2041
-
Levodopa dosing regimen
Patent 12,201,596
Issued: January 21, 2025
Inventor(s): D'Souza; Richard et al.
Assignee(s): Amneal Pharmaceuticals, LLC (Bridgewater, NJ)The invention is a method for treating patients with post-encephalitic parkinsonism, parkinsonism that may follow carbon monoxide intoxication, or parkinsonism that may follow manganese intoxication by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.
Patent expiration dates:
- December 21, 2041✓
- December 21, 2041✓
- December 21, 2041✓
- December 21, 2041
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- August 7, 2027 - NEW PRODUCT
More about Crexont (carbidopa / levodopa)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: dopaminergic antiparkinsonism agents
- En español
Patient resources
Other brands
Sinemet, Rytary, Sinemet CR, Duopa, ... +2 more
Professional resources
Other brands
Sinemet, Rytary, Sinemet CR, Duopa, ... +2 more
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
